688192 迪哲医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-7.559-102.722-162.312-84.976-34.871
总资产报酬率 ROA (%)-3.177-32.366-52.624-61.913-30.491
投入资产回报率 ROIC (%)-3.656-39.241-64.724-71.379-33.498

边际利润分析
销售毛利率 (%)95.92595.72797.41196.478--
营业利润率 (%)-38.162-95.660-261.545-1,213.308--
息税前利润/营业总收入 (%)-35.329-91.986-254.688-1,207.359--
净利润/营业总收入 (%)-38.295-95.929-261.087-1,213.419--

收益指标分析
经营活动净收益/利润总额(%)116.758111.200106.098104.851106.708
价值变动净收益/利润总额(%)-7.010-3.302-1.538-2.033-5.730
营业外收支净额/利润总额(%)-0.0250.100-0.1760.0000.000

偿债能力分析
流动比率 (X)2.8202.2151.2722.0305.928
速动比率 (X)2.7792.1781.2161.9785.908
资产负债率 (%)59.00556.84788.36043.28815.535
带息债务/全部投入资本 (%)52.97347.74682.01127.8060.561
股东权益/带息债务 (%)86.714106.68417.448242.22217,006.872
股东权益/负债合计 (%)69.43875.80412.758131.011543.703
利息保障倍数 (X)-12.515-24.409-39.802-202.96590.190

营运能力分析
应收账款周转天数 (天)56.03238.40637.778189.449--
存货周转天数 (天)302.110426.2941,305.8151,597.977--